VRNA vs. EMA

Last updated Jun 9, 2026

VRNA (Verona Pharma plc) and EMA (Emera Inc) are both stocks. VRNA operates in Biotechnology (Healthcare), while EMA operates in Utilities - Regulated Electric (Utilities). At a 0.14 correlation, their price movements are largely independent.

Performance

VRNA vs. EMA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Verona Pharma plc (VRNA) and Emera Inc (EMA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

EMA

• 1D: -1.29%
• 1M: -2.87%
• YTD: 5.65%
• 6M: 10.36%
• 1Y: 20.76%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

VRNA vs. EMA - Yearly Performance Comparison

	2026 (YTD)	2025
VRNA Verona Pharma plc	0.00%	41.40%
EMA Emera Inc	5.65%	11.17%

Correlation

The correlation between VRNA and EMA is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.12
Correlation (All Time) Calculated using the full available price history since May 28, 2025	0.14

Fundamentals

Market Cap VRNA : $9.72B EMA : $15.54B
EPS VRNA : -$0.69 EMA : $3.55
PS Ratio VRNA : 57.97 EMA : 1.79
PB Ratio VRNA : 34.92 EMA : 1.69
Total Revenue (TTM) VRNA : $167.65M EMA : $8.59B
Gross Profit (TTM) VRNA : $159.52M EMA : $2.83B
EBITDA (TTM) VRNA : -$40.86M EMA : $2.56B

Return for Risk

VRNA vs. EMA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EMA

EMA Risk / Return Rank: 83
EMA Sharpe Ratio Rank: 83
EMA Sortino Ratio Rank: 80
EMA Omega Ratio Rank: 77
EMA Calmar Ratio Rank: 86
EMA Martin Ratio Rank: 87

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VRNA vs. EMA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Verona Pharma plc (VRNA) and Emera Inc (EMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	VRNA	EMA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	1.54	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	1.38	—

Drawdowns

Drawdown Indicators

	VRNA	EMA	Difference
Max Drawdown Largest peak-to-trough decline	—	-5.93%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-5.93%	—
Current Drawdown Current decline from peak	—	-4.74%	—
Average Drawdown Average peak-to-trough decline	—	-1.76%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	2.20%	—

Volatility

Volatility by Period

	VRNA	EMA	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	4.67%	—
Volatility (6M) Calculated over the trailing 6-month period	—	10.21%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	13.60%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	13.72%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	13.72%	—

Dividends

VRNA vs. EMA - Dividend Comparison

VRNA has not paid dividends to shareholders, while EMA's dividend yield for the trailing twelve months is around 3.87%.

Position	TTM	2025
EMA Emera Inc	3.87%	2.12%
VRNA Verona Pharma plc	0.00%	0.00%

Financials

VRNA vs. EMA - Profitability Comparison

The chart below illustrates the profitability comparison between Verona Pharma plc and Emera Inc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

EMA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Emera Inc reported a gross profit of 756.95M and revenue of 2.48B. Therefore, the gross margin over that period was 30.5%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

EMA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Emera Inc reported an operating income of 626.62M and revenue of 2.48B, resulting in an operating margin of 25.3%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

EMA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Emera Inc reported a net income of 583.50M and revenue of 2.48B, resulting in a net margin of 23.5%.

Frequently Asked Questions

Can I hold both VRNA and EMA in my portfolio?

VRNA and EMA have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.